Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
clinical trials
6
×
life sciences
national blog main
san francisco blog main
san francisco top stories
6
×
boston blog main
boston top stories
fda
national top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
fremanezumab
teva pharmaceutical
calcitonin gene-related peptide
deals
eptinezumab
erenumab
galcanezumab
immunotherapy
migraine
What
approval
6
×
drug
fda
developed
new
won
amgen
class
companies
marketing
medicines
migraine
nod
oral
wins
agency
aimmune
allergy
amgen’s
approved
arguments
awarded
big
bio
biogen’s
biopharmaceutical
blueprint
cancer
candidate
candidates
carries
commercialized
competitors
convo
currently
decades
drugs
earlier
europe
european
Language
unset
Current search:
approval
×
biotech
×
" clinical trials "
×
" san francisco top stories "
×
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines